middle.news
NSB Secures FDA Pre-IND Meeting for StemSmart Phase 2 Trial in Refractory Crohn’s
8:22am on Thursday 13th of August, 2026 AEST
•
Biotechnology
Read Story
NSB Secures FDA Pre-IND Meeting for StemSmart Phase 2 Trial in Refractory Crohn’s
8:22am on Thursday 13th of August, 2026 AEST
Key Points
FDA schedules Pre-IND meeting for 31 August 2026
StemSmart™ targets treatment-resistant Crohn’s disease
Phase 2 trial design to be reviewed for US patient suitability
IND submission planned by late 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuroscientific Biopharmaceuticals (ASX:NSB)
OPEN ARTICLE